Bioequivalence of netupitant and palonosetron (NEPA) oral suspension and hard capsules in healthy individuals: results from an open-label, randomized, two-treatment, four-period, two-sequence replicative design trial
Supportive Care in Cancer · 2026-02 · 34 (2)
DOI: 10.1007/s00520-026-10345-2 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Supportive Care in Cancer, online erschienen am 02.02.2026. Verfasst von Edis Gasanin und 3 weiteren Autor:innen. Beteiligte Einrichtung: CRS Clinical Research Services Mannheim GmbH (Part of hVIVO), Mannheim, Germany. Edis.Gasanin@crs-group.de. Hauptthemen laut MEDLINE: Palonosetron, Antiemetics, Pyridines. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
PURPOSE: NEPA, a fixed-antiemetic combination of netupitant and palonosetron, is available via two administration routes (oral and intravenous). A new oral suspension was developed to offer a more convenient option for patients. This study evaluated the bioequivalence between the oral capsule and the oral suspension. METHODS: Open-label, randomized, single-center phase I trial conducted according to a two-treatment, four-period, two-sequence replicative design. Two treatments were investigated for bioequivalence: a 10-mL oral suspension (Test [T]) and the hard capsule (Reference [R]), both containing 300 mg netupitant/0.5 mg palonosetron. Healthy individuals were randomized (1:1) to receive two doses of both Test and Reference formulations, in either T-R-T-R or R-T-R-T sequence. The primary objective was to demonstrate AUC0-t bioequivalence of netupitant and palonosetron after a single dose of Test and Reference formulations. RESULTS: In total, 72 participants were included. The geometric mean plasma concentration-time profiles of netupitant and palonosetron were similar for the Test and Reference formulations. The AUC0-t geometric means of both analytes were similar for the Test and Reference formulations. The 90% confidence interval of the Test/Reference ratios for AUC0-t of netupitant and palonosetron were within the acceptance range for bioequivalence of 80-125%. The AUC0-t variability was moderate for netupitant and low for palonosetron. Both formulations were well tolerated. CONCLUSION: The NEPA oral suspension is pharmacokinetically bioequivalent to the capsule formulation in healthy individuals, with no new safety concerns. These findings support NEPA oral suspension as a potentially beneficial option for patients who prefer an oral suspension over a hard capsule and for those with swallowing difficulties. EUCT Number: 2023-504355-28-00 (25/08/2023).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CRS Clinical Research Services Mannheim GmbH (Part of hVIVO), Mannheim, Germany. Edis.Gasanin@crs-group.de.
- Helsinn Healthcare SA, Lugano, Switzerland.
- CRS Clinical Research Services Mannheim GmbH (Part of hVIVO), Mannheim, Germany.
Zitieren
APA
Gasanin, E., Bezzo, R., Spinelli, T., & Seitz, F. (2026). Bioequivalence of netupitant and palonosetron (NEPA) oral suspension and hard capsules in healthy individuals: results from an open-label, randomized, two-treatment, four-period, two-sequence replicative design trial. Supportive Care in Cancer, 34(2). https://doi.org/10.1007/s00520-026-10345-2
Vancouver
Gasanin E, Bezzo R, Spinelli T, Seitz F. Bioequivalence of netupitant and palonosetron (NEPA) oral suspension and hard capsules in healthy individuals: results from an open-label, randomized, two-treatment, four-period, two-sequence replicative design trial. Supportive Care in Cancer. 2026;34(2). doi:10.1007/s00520-026-10345-2
BibTeX
@article{Gasanin2026,
author = {Gasanin, Edis and Bezzo, Riccardo and Spinelli, Tulla and Seitz, Friedeborg},
title = {Bioequivalence of netupitant and palonosetron (NEPA) oral suspension and hard capsules in healthy individuals: results from an open-label, randomized, two-treatment, four-period, two-sequence replicative design trial},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {2},
doi = {10.1007/s00520-026-10345-2}
}
EUVIMED